Samsung Biologics Co.,Ltd. (KRX:207940)

Samsung Biologics Revenue

Samsung Biologics had revenue of 1.26T KRW in the quarter ending March 31, 2026, with 25.77% growth. This brings the company's revenue in the last twelve months to 4.81T, up 35.63% year-over-year. In the year 2025, Samsung Biologics had annual revenue of 4.56T with 30.31% growth.

• Revenue (ttm): 4.81T
• Revenue Growth: +35.63%
• P/S Ratio: 12.88
• Revenue / Employee: 926.77M
• Employees: 5,047
• Market Cap: 62.03T

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	4.56T	1.06T	30.31%
Dec 31, 2024	3.50T	-197.44B	-5.34%
Dec 31, 2023	3.69T	693.29B	23.10%
Dec 31, 2022	3.00T	1.43T	91.41%
Dec 31, 2021	1.57T	403.23B	34.62%

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 3, 2026

Data Sources Report a data error